novo nordisk semaglutide clinical trials New Wegovy trial finds surprising benefits that go way beyond weight loss Oral semaglutide (Rybelsus®) receives FDA

Amin Sabet, an endocrinologist at UMass Memorial Medical Center

10.1016/j.jacc.2008.10.033

The rationale is that even sub-therapeutic doses activate the GLP-1 and GIP receptors enough to produce noticeable appetite modulation without the gastrointestinal side effects that trouble many users during standard initiation

GLP-1 drugs mimic a naturally occurring hormone called glucagon-like peptide-1, which plays a role in regulating blood sugar and appetite

Con artists will try to override your reservations about a transaction by giving it a false sense of urgency

Mansur RB, Fries GR, Trevizol AP, Subramaniapillai M, Lovshin J, Lin K, et al